SC: Cheque Dishonour Complaint Can't be Quashed Pre-Trial if Sec 138 NI Act Conditions Met || SC: Personal Hearing Not Required Before Banks Declare Account ‘Fraud’ || Supreme Court Faults UCO Bank For Attempt to Stall Employee’s VRS Through Show Cause Notice || SC: PwD Post in Unreserved Category Can be Filled by SC/ST/OBC Candidates With Disabilities || Delhi HC: FSSAI Has No Authority to Regulate Animal Feed || Gauhati HC: Adult Son Pursuing Studies is Not Entitled to Maintenance under Section 125 CrPC || Cal HC Upholds Divorce, Rules False Cases by Wife And 17-Year Separation Constitute Mental Cruelty || Supreme Court: Calling Someone ‘Bastard’ In Heated Exchange Isn’t Obscenity under IPC Section 294 || Supreme Court: Even a Single Tainted Public Work Award Violates Article 14 || Supreme Court Upholds Lease Cancellation, Denies Relief for Failure to Develop Allotted Land

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :